Pairwise testing for ESPL1 and PTTG1 showed significant differences between CML groups (R, NR) and controls, i.e., elevated transcript levels (FC = fold change) in the CML groups when compared to the control group. This evidence concerns the gene PTTG1 and chronic myelogenous leukemia, BCR-ABL1 positive.